INTRODUCTION
============

Epimedii Herba, the aerial parts of Epimedium species (Berberidaceae), has been traditionally used in Korea and China to treat coronary heart disease, male impotence, improve female health, and strengthen bones [@B026]; [@B018]. More than 130 compounds have been isolated from Epimedium species, including prenylated flavonoids and their glycosides. Among these compounds, icariin (ICI), epimedin A, B, C, and hyperin are the main components in Epimedii Herba [@B004]; [@B012]). ICI, which is the principal Epimedium prenylflavonoid, significantly inhibits human phosphodiesterase-5 and induces nitric oxide synthase expression in corpus cavernosum smooth muscle [@B016]; [@B005].. In animal studies, ICI and Epimedium flavonoid administration inhibits bone resorption, stimulates bone formation, prevents osteoporosis in ovariectomized rats [@B027], and improves erectile function in aged male rats [@B019]. Icaritin (ICT), which is the aglycone of ICI, stimulates estrogen-driven cell proliferation and estrogen responsive element (ERE)-dependent reporter genes [@B023]; [@B007].

Phytoestrogens are plant-derived polyphenolic compounds that produce estrogenic or antiestrogenic-like biological effects in the body. These compounds are found in a wide variety of foods and have been widely marketed as a natural alternative to estrogen replacement therapy. Previous studies have shown that the estrogenic activity of phytoestrogens has beneficial health effects, including a lowered risk for osteoporosis, heart disease, breast cancer, and menopausal symptoms. However, phytoestrogens may interfere with the role of E2 by acting as an endocrine disruptor and causing adverse health effects [@B020]. Clinical and experimental studies examining the impact of soy or soy phytoestrogen consumption on human health have produced mixed and often conflicting results. Phytoestrogens may interfere with endogenous estrogen action either by acting as agonists when endogenous estrogen levels are low or by acting as antagonists when endogenous estrogen levels are high [@B007]. Emerging evidence suggests that exposure to dietary phytoestrogens may pose a risk to some groups, particularly infants and the unborn [@B022]; [@B002]. Consequently, the question of whether or not phytoestrogens are beneficial or harmful to human health remains controversial [@B020].

Recently, we assessed the estrogenic and antiestrogenic activity of Epimedii Herba extract (Ext), ICI, and ICT ([Fig.1](#F001){ref-type="fig"}) using an *in vitro* estrogen receptor (ER) α or β-mediated ERE-driven reporter gene assay and an *in vivo* uterotrophic assay. ICI and ICT were used as a representative glycoside and aglycone of prenylflavonoid from Ext, respectively. We found that although ICI did not have any *in vitro* estrogenic or antiestrogenic activity mediated by ER α or β, it displayed the highest estrogen activity among the three groups in the *in vivo* uterotrophic assay using adult rat. The dried extract contains approximately 2.56 ± 0.25% ICI and has *in vitro* and *in vivo* estrogenic activity [@B007].

To examine any potential hormone-like effects of Epimedii Herba and its compounds ICI and ICT on the neuroendocrine axis during the sensitive period of puberty, the effects of Ext, ICI and ICT on female sexual development was evaluated after peripubertal administration using a modified protocol of the rodent 20-day pubertal female assay [@B010].

MATERIALS AND METHODS
=====================

Preparation and identification of major compounds from Epimedium koreanum
-------------------------------------------------------------------------

Epimedii Herba was purchased from a farmer in Chulwon (Kangwondo, Korea) and authenticated by Prof. Je-Hyun Lee at the College of Oriental Medicine at Dongguk University (Gyeongju, Korea).

Preparation and identification of Ext, ICI, and ICT were described by [@B007]. ICI was determined to be the most abundant flavonoid in Ext (2.56 ± 0.25%); however, ICT was not detected.

Animals
-------

Animal studies were conducted in accordance with the institutional guidelines for care and use of laboratory animals, and the experimental protocol was approved by the Animal Ethics Committee at Korea University, Seoul, Korea.

Female Sprague-Dawley rats (14-day timed pregnant) were purchased from Orient Bio Inc. (Sungnam, Korea). Pregnant rats were housed individually in polycarbonate cages and maintained under controlled temperature (23 ± 1℃), humidity (35 ± 5%), and light (12 h light/12 h dark) conditions. Food and water were freely available. Pregnant dams were allowed to deliver their pups naturally. The day of birth was recorded as postnatal day (PND) 0. Upon weaning on PND 21, females were ranked by body weight (BW) and allocated into five groups based on BW. Littermates were equally distributed among treatment groups.

Experimental design for female rat sex maturation
-------------------------------------------------

Females in the five treatment groups received either saline (control group, Con) or estrogen (E2 group; 1 μg/3 ml/kg/day), and Ext (200 mg/3 ml/kg/day), ICI (20 mg/3 ml/kg/day) or ICT(20 mg/3 ml/kg/day). All test samples, except E2, were administered by oral gavage from PND21 through PND40. E2 was administered by subcutaneous injection. BWs were recorded daily, and the dose administered each day was adjusted for BW. Females were killed on PND 41, and blood was collected to determine the levels of E2 and testosterone. The weights of the kidney, liver, adrenal glands, ovary, uterus, and pituitary gland were recorded.

Assessment of puberty and estrous cyclicity
-------------------------------------------

All females were checked daily for vaginal opening (VO) starting at PND22. The day of complete VO and the BW on that day were recorded. Vaginal lavage fluid was collected once per day by repeatedly pipetting 0.9% saline into the vagina until VO occurred. The lavage fluid was placed on a glass slide, sprayed with Spraycyte fixative (Fisher Scientific, Pittsburgh, PA, USA), and stained with hematoxylin and eosin (Sigma, St. Louis, MO, USA) to determine the estrous cycle stage, as previously described [@B003]. The smear was observed immediately under low magnification (100× or 200×) using a light microscope. The vaginal smears were classified as diestrus (presence of leukocytes), proestrus (presence of nucleated epithelial cells), or estrus (presence of cornified epithelial cells) as described by [@B008]. Extended estrus was defined as samples containing cornified cells with no leukocytes for 3 or more days, and extended diestrus was defined as samples containing the presence of leukocytes for 4 or more days [@B011].

![Chemical structures of 17β-estradiol, icariin, and icaritin.](ooomb4-20-189-g001){#F001}

###### 

Primer sequences used in the PCR reactions

  ---------- --------------------------------------- ---------------
  Genes      Primer sequences                        Amplicon (bp)
                                                     
  ER alpha   \(F\) TCA CAC CAA AGC CTC GGG AA        879
             \(R\) GGC CAA AGG TTG GCA GCT CT        
  ER beta    \(F\) GCG ACC CAT TGC CAA TCA TC        801
             \(R\) GAA AAT GAG CTT GCC GGG GT        
  C3         \(F\) TGG TGC GCA ATG AAC AGG TG        805
             \(R\) AGC CAT TTG ACA GCC CCA CA        
  CaBP9K     \(F\) AGC TGG GCA CAG TGG CAA AA        839
             \(R\) CAC ATG CAG GCA AAA TGC CA        
  PR         \(F\) TTC ACG TGC CCA TTC TGC CT        862
             \(R\) TTA TGC TGC CCT TCC ATC GC        
  IGFBP1     \(F\) TGC CGG AGT TCC TAA CTG TTG TTT   802
             \(F\) TGC CGG AGT TCC TAA CTG TTG TTT   
  ---------- --------------------------------------- ---------------

Clinical signs and BWs
----------------------

Each animal was observed at least once daily throughout the study period for clinical signs of toxicity related to chemical treatment. On working days, all cages were checked for dead or moribund animals in the morning and afternoon. The BW of each rat was measured daily just prior to treatment.

Hormonal measurements
---------------------

Blood was collected from the abdominal aorta approximately 24 h after the last test compound treatment. Serum was prepared immediately and stored at -80℃ until analyzed for serum hormone concentrations. Commercially available radio-immunoassay kits were used to measure serum concentrations of thyroid stimulating hormone (TSH) and E2 (Amersham Corp., Piscataway, NJ, USA).

![Changes in the body weight of female rats during treatment with Epimedii extract, ethinyl estradiol, icariin, and icaritin. Animals were dosed daily starting at postnatal day (PND) 21 and treatment was continued until necropsy on PND 41. Data are mean ± SE of 10 animals per treatment group. \*Significantly different from vehicle control (ANOVA), p\<0.05.](ooomb4-20-189-g002){#F002}

![Effects of Epimedii Herba extract, icariin, and icaritin on vaginal opening (VO) in the female pubertal onset assay. Each animal was examined daily for VO beginning on postnatal day (PND) 22. The number of rats that underwent VO was cumulative in each group.](ooomb4-20-189-g003){#F003}

RNA preparation and reverse transcription polymerase chain reaction (RT-PCR) analysis of estrogen-related mRNA expression in ovary and liver
--------------------------------------------------------------------------------------------------------------------------------------------

Levels of estrogen responsive protein mRNA were analyzed by RT-PCR. Total RNA was extracted from rat liver and ovarian tissue using Easyblue (Intron Biotechnology Co., Dajeon, South Korea) following the manufacturer's procedure. Total RNA (5 μg) was reversed transcribed in a final volume of 50 μl using M-MLV Reverse Transcriptase in the presence of oligo-dT primer, deoxy-NTP and Rnasin (Promega, Madison, WI, USA) for 60 min at 42℃, after denaturation for 5 min at 95℃.The primers used and the PCR conditions are listed in [Table 1](#T001){ref-type="table"}.

Statistical analysis
--------------------

Data are reported as mean ± SD. Data for the VO day, BW, and organ weight of the rats were evaluated using a one-way analysis of variance with a level of significance set at *p*\<0.05.

RESULTS
=======

Clinical signs and body weights
-------------------------------

No mortality or clinical signs of toxicity were observed in any of the treatment groups. A statistically significant decrease in mean necropsy BW was observed at PDN 41 for rats treated with E2 (*p*\<0.05). Ext, ICI, and ICT had no significant effects on mean necropsy BW or BW gains during the treatment period from PND 21 to PND 41 ([Fig.2](#F002){ref-type="fig"} ).

Vaginal opening
---------------

VO was used as an indicator of puberty. The mean age and

###### 

Mean age and body weights at the time of vaginal opening in female rats treated with ethinyl estradiol, Epimedii Herba extract, icariin, or icaritin from postnatal day (PND) 21 for 20 days

  ----------- ----------------- ------------------
  Treatment   Mean age          Mean body weight
                                
  Control     36.6 ± 1.01       130.0 ± 9.21
  E2          26.6 ± 0.53\*\*   68.7 ± 5.59\*\*
  Ext         35.6 ± 0.88       120.2 ± 12.19
  Icariin     35.0 ± 1.32       120.3 ± 10.91\*
  Icaritin    33.9 ± 1.83\*     117.6 ± 11.41\*
  ----------- ----------------- ------------------

Mean ± SD (n=9 animals per treatment group). \**p*\<0.05, \*\**p*\<0.01.

###### 

Effects of Epimedii Herba extract, icariin, and icaritin on the estrus cycle in female rats

  ----------- ------------- -------------------- -------------
  Treatment   Days                               
                                                 
              Proestrus     Estrus + Metestrus   Diestrus
                                                 
  Control     0.89 ± 0.33   1.78 ± 0.44          3.00 ± 0.50
  E2          1.00 ± 0.53   11.67 ± 1.50\*       3.33 ± 1.22
  Ext         0.89 ± 0.33   1.78 ± 0.97          3.89 ± 0.93
  ICI         0.78 ± 0.44   2.78 ± 0.67\*        3.44 ± 0.88
  ICT         0.67 ± 0.50   4.00 ± 0.71\*        3.44 ± 1.51
  ----------- ------------- -------------------- -------------

Mean ± SD (n=9 animals per treatment group). ^\*^Significantly different from the control group (*p*\<0.05).

![Estrogen-linked organ weights of female rats at necropsy on postnatal day (PND) 41 after treatment with Epimedii extract, ethinyl estradiol, icariin, and icaritin. (A) The ovary, (B) uterus, and (C) pituitary gland were isolated and weighed. Data are mean ± SE of 10 animals per treatment group. \*Significantly different from the vehicle control (ANOVA), p\<0.05.](ooomb4-20-189-g004){#F004}

BW at VO in the control animals were 36.6 ± 1.01 days (range, 35-38 days) and 130.0 ± 9.21 g, respectively. E2 treatment significantly accelerated the time of VO to 26.6 days and decreased mean BW to 68.7 ± 5.59 g ([Fig. 3](#F003){ref-type="fig"}, [Table 2](#T002){ref-type="table"}). The day of VO decreased in each Epimedii group ([Table 2](#T002){ref-type="table"}), particularly in the ICT group (*p*\<0.05).

Estrous cycle
-------------

The estrus cycles of individual animals were observed starting the day following VO until the end of the study. The number of days in the complete estrus cycle increased dramatically with E2 treatment. This increase in estrus cycle duration in the E2-treated rats was due to an extended estrus cycle of 8-11 days when compared to that of the control (1-3 days)

![Effect of Epimedii Herba extract, icariin, and icaritin onserum estradiol levels in female rats on postnatal day (PND) 41 inthe female pubertal onset assay. Serum hormone concentrationswere evaluated individually in all groups of rats regardless of estrus stage. Data are mean ± SE of 10 animals per treatment group.\*Significantly different from the vehicle control (ANOVA), p\<0.05.](ooomb4-20-189-g005){#F005}

([Table 3](#T003){ref-type="table"}). Treatment with ICI and ICT significantly increased the duration of the estrus cycle (ICI, 2.78 days; ICT, 4.0 days; control, 1.78 days), whereas proestrus and diestrus did not change significantly in the Epimedii Herba groups.

Organ weights
-------------

No signs of apparent organ toxicity were observed in any of the treatment groups. Rats in the E2 group had significantly lower ovarian weights and higher uterus and pituitary gland weights than those of the other groups ([Fig.4](#F004){ref-type="fig"} ). However, rats in the Ext, ICI, and ICT groups had significantly higher ovarian and uterus weights than those in the Con group. Pituitary gland weight increased significantly in the E2 and ICT groups but not in the Ext and ICI groups. No significant difference in the weights of the liver, kidney, or adrenal glands was observed (data not shown).

Serum gonadal sex hormones
--------------------------

Serum hormone concentrations were evaluated individually in all rats regardless of estrus cycle stage. Mean serum estradiol level decreased significantly in the E2 group. However, Ext, ICI, and ICT tended to have higher blood estradiol levels, but the increase was not significant except ICT ([Fig.5](#F005){ref-type="fig"} ). Serum levels of TSH were below the detection limit in all groups (data not shown).

Estrogen response gene expression in the liver, uterus, and ovaries
-------------------------------------------------------------------

The expression of well-known estrogen related genes was evaluated in the liver, uterus, and ovary to further access the estrogenic activity of Epimedii Herba in rats. Estrogen effects in the liver were investigated by measuring the expression of calcium binding protein 9kDa (CaBP9K) and insulin like growth factor binding protein 1 (IGFBP1), which are reasonably good markers for the effect of estrogen on the liver [@B009].

Both the E2 and ICT groups showed significantly up-regulated expression of the IGFBP-1 gene, and the Ext and ICI groups had slightly up-regulated levels of these proteins in liver tissue ([Fig.6](#F006){ref-type="fig"} A). CaBP9k expression was up-regulated in the E2 and ICT groups. Both the Ext and ICI treatments elevated CaBP9k and IGFBP-1 gene expression in the liver([Fig.6](#F006){ref-type="fig"} A). ER-α, C3, and progesterone receptor (PR) mRNA

![Effect of Epimedii Herba extract, icariin, and icaritin on the expression of estrogen response genes in (A) the liver, (B) uterus, and (C) ovary of rats at postnatal day (PND) 41 in the female pubertal onset assay. Estrogen response gene expression was determined by semiquantitative RT-PCR.](ooomb4-20-189-g006){#F006}

levels in the uterus were also assessed ([Fig.6](#F006){ref-type="fig"} B). The levels of ER-α were down-regulated following treatment with E2 and ICT, whereas C3 and PR mRNA was up-regulated ([Fig.6](#F006){ref-type="fig"}B). E2 treatment caused a significant reduction in the level of ER-α mRNA ([Fig.6](#F006){ref-type="fig"} C). ER-β mRNA was expressed in rats of all treatment groups. An analysis of uterine wet weight allows for only a partial evaluation of the estrogenic potency and mode of action. Additional endpoints such as changes in estrogen sensitive gene expression permit a more detailed analysis of responses.

DISCUSSION
==========

Epimedii Herba not only stimulates sexual activity in males by tonifying the kidney and strengthening *yang* [@B005] but also functions as a phytoestrogen, which can have potential health benefits in females by countering menopausal symptoms and lowering the incidence of hormone-dependent diseases including breast cancer [@B021]. Epimedii Herba has been used as a traditional herbal medicine and a tea to improve health in rural areas of Korea. We previously reported that although Ext and ICT, but not ICI, exhibits *in vitro* estrogen receptor α and β-mediated estrogenic activity, ICI displays higher estrogenic and anti-estrogenic activities than those of Ext or ICT in ovariectomized adult rats [@B007]. In this study, we found that Epimedii Herba affected maturation of the female reproductive system by acting as an exogenous estrogen in weanling rats.

The onset of puberty in female rats includes VO and first ovulation. We used VO and the first estrous cycle as markers of the end of puberty. VO in the rat commonly takes place between PND 33 and 42, although variations occur between strains and different colonies of the same strain [@B011]; [@B014]. In this study, rats had a mean VO age of 36.5 ± 1.61 days (range, 35-38 days), which was consistent with previous studies. E2 (1.0 μg/kg/day) treatment significantly advanced the day of VO (10 days) and decreased BW at VO as expected. Although ICT only decreased the time to VO by 2.7 days and significantly reduced BW at the VO day, all groups tended to develop precocious VO ([Table 2](#T002){ref-type="table"}, [Fig. 3](#F003){ref-type="fig"}). A normal cycle is generally defined as 4-5 days and contains 1-2 days of estrus [@B011]; [@B014]. The E2 group produced a persistent estrus state, and ICI and ICT increased significantly by 1.0 and 2.22 days, respectively, in estrus days when compared to those of the control ([Table 3](#T003){ref-type="table"}). Taken together, these results indicate that although Ext possessed very weak estrogenic activity, these treatments advanced pubertal timing in the order of ICT, ICI, and Ext.

Most of the compounds identified from Ext including the major component of ICI were prenylflavonoid glycosides, which possess very weak or non-estrogenic activity *in vitro*. The potency of the *in vitro* ER α or ER β-mediated estrogenic activity of these compounds is as follows: ICT \> Ext \> ICI [@B007]. However, ICI displayed higher *in vivo* estrogenic activity than that of ICT in the adult female and ICT produced the strongest estrogenic activity in the prepubertal onset assay. Interestingly, Ext displayed significant estrogenic activity in adult female rats but not in young rats. The discrepancies between adult and pre-pubertal rats with regard to the potency of estrogenic activity in Ext, ICI, and ICT might be due to the rates of absorption, metabolism, and clearance. Absorption of intact glycosides is much slower than the corresponding aglycones, and intestinal and microbial glycosidases are a critical first step in the intestinal and microbial disposition of flavonoid glycosides [@B017]. [@B025] reported that ICI is rapidly metabolized to icariside II by bacteria in the rat intestine, where icariside II is absorbed faster than ICI, and relatively high concentrations of icariside II are detected in plasma after intragastric administration of ICA to rats. Phase II metabolism such as glucuronidation in young rats would be limited, because the capacity for phase II metabolism is underdeveloped relative to adults [@B006]; [@B013]. Therefore, intestinal bacteria might be underdeveloped in young rats compared to adult rats; thus, the glycoside form of flavonoids in Ext or ICI could not be readily converted to their aglycone form and the rate of absorption might have been low compared to ICT in prepubertal rats.

The weights of the uterus and pituitary gland increased significantly following the E2 and ICT treatments but not after the Ext and ICI treatments. However, the profile of ovary weight changes was different. Ovary weight decreased significantly following E2 treatment (*p*\<0.05) but increased following the Ext, ICT, and ICT treatments ([Fig.4](#F004){ref-type="fig"} ). The blood estrogen profile among these four groups was similar to that of ovarian weight ([Fig.6](#F006){ref-type="fig"} ). E2 treatment significantly lowered serum estradiol levels, whereas Epimedium Herba treatment elevated serum estradiol levels in the following order: ICT, ICI, and Ext (Fig.8). Estrogens are synthesized in the ovary. Thus, exogenous estrogen might stimulate feedback inhibition of estrogen synthesis via the hypothalamus-pituitary-ovary axis resulting in ovarian atrophy. The changes in gene expression were very similar between E2 and ICT in the uterus, ovary and liver, except for aromatase. Therefore, atrophy of the ovary might be related to aromatase activity, i.e., induction of aromatase expression in ovaries or stimulation of aromatase activity. Although further study is needed, aromatase mRNA expression in the ovary of the E2 and ICI groups was correlated with the level of blood estrogen ([Fig.5](#F005){ref-type="fig"} ). Thus, the estrogenic effect of ICT might be due not only to estrogenic activity but also to elevated blood levels of E2.

Relatively few phytoestrogens or natural plant extracts have been studied in the context of pubertal timing compared to environmental chemicals, and most of these studies evaluated the effects of soy-related phytoestrogens or formula [@B015]; [@B013]. Although the estrogenic activities of Ext and ICI were weak, weaning rats (21 days of age) were exposed to relatively low doses of the compounds. For example, we used ICI and ICT at doses of 10 mg/kg, and Ext at 200 mg, which can be obtained from 1 g of dried Epimidii Herba (about 22% yield). [@B024] reported that prepubertal dietary exposure to coumestrol (0.01% concentration, d22-60) in female rats accelerated VO by 4 days and produced irregular cycles at 116-131 days. They suggested that chronic coumestrol treatment may have induced some permanent changes in reproductive function. The pituitary/hypothalamic axis in peripubertal female Sprague-Dawley rats is less sensitive than that of adult female Sprague-Dawley rats [@B001]. Therefore, the strength of the estrogenic activity of phytoestrogens or plant extracts could have a greater affect on pubertal timing and plant estrogens at natural dietary levels and produce significant agonistic actions in several estrogen-dependent tissues and processes.

The estrogenic effect of phytoestrogens has been widely evaluated in terms of human health. However, phytoestrogens can also interfere with endogenous estrogen action either by acting as agonists at times of low endogenous estrogen or by acting as antagonists at times of higher endogenous estrogen levels. Thus, estrogenic substances that are not only synthetic chemicals but also plant extracts may act as endocrine disruptors and may alter sex maturation in male and female children who are sensitive to sex hormones.

This study was supported by a grant from the Korea Science and Engineering Foundation (KOSEF R03-2001-000-00024-0), a grant (05142KFDA624) from the Korea Food & Drug Administration in 2005, and the Korea University Grant 2008.
